FinGraph AI values Pfizer Inc. with a deterministic 3-stage discounted cash flow (DCF) model built from PFE's SEC 10-K/10-Q filings and live market data — then cross-checks it against peer multiples, forensic-accounting scores and a reverse-DCF. Run the full report in under a minute.
Run the live PFE report →A 3-stage unlevered DCF with a CAPM/WACC build-up, compared directly to PFE's market price so you can see the premium or discount to the baseline.
The growth rate the market is currently pricing into Pfizer Inc., measured against its real historical performance.
Altman Z (distress), Piotroski F (fundamental strength) and Beneish M (earnings-manipulation) scores from the filings.
Pfizer Inc. benchmarked on P/E, EV/EBITDA, P/S and margins against a live comparable-company set.
Pfizer Inc. (NYSE: PFE) is covered in FinGraph AI's Healthcare universe. Every figure in the report traces to PFE's SEC EDGAR filings and live market data — there are no hand-entered numbers, and the DCF is deterministic rather than LLM-estimated. This page is informational and updates when you run the live report.
Value PFE now →Informational research only — not investment advice, and not a recommendation to buy or sell any security. FinGraph AI is not a registered investment adviser. Figures derive from SEC EDGAR filings and market data and may differ from other sources.